Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma
Commercial Sponsor
Hoffmann-La Roche
Summary
Eligible participants will be randomised to three parts: a safety run-in (split into cohort 1.1 (for CPI and experienced melanoma participants) and 1.2 (for CPI experienced melanoma participants only) and two expansion parts (part 2 and part 3). Part 2 will commence once all participants in cohort 1.1 have completed observation; part 3 will commence once all participants in cohorts 1.1 and 1.2 have completed observation.